Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

EW vs RMD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RMD Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–4 Matrix Metrics)

RMD Overall Winner 6-Pillar Tally: EW 2 – 4 RMD Matrix Metrics: EW 4 – 6 RMD

As of Nov 16, 2026, ResMed Inc. (RMD) is the stronger overall head-to-head candidate over Edwards Lifesciences Corp (EW) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). EW carries a Unified Composite Score of 31.5/100 (SELL) at $106.66 (31.6x Forward P/E, 28.8% operating margin), whereas RMD carries 59.0/100 (HOLD) at $239.34 (19.8x Forward P/E, 34.0% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EW vs RMD
EW NYSE
Edwards Lifesciences Corp
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$106.66
-0.46% 1D
Market Cap $60.8B
TTM Revenue $6.67B
Forward P/E 31.6x
Beta / 30D Vol 0.44β · 24% Vol
Unified Composite Score
31.5 / 100 SELL
Tech 50.0 Fund 29.0 Flow 51.0 Mom 44.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.7% over 20 days), RSI 79
RSI-14: 79.4 · SMA20: $97.03 · SMA50: $90.77
RMD NYSE Head-to-Head Winner
ResMed Inc.
Surgical & Medical Instruments & Apparatus
$239.34
-0.08% 1D
Market Cap $33.6B
TTM Revenue $5.73B
Forward P/E 19.8x
Beta / 30D Vol 0.41β · 43% Vol
Unified Composite Score
59.0 / 100 HOLD
Tech 62.0 Fund 59.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.1% over 20 days), RSI 55
RSI-14: 54.8 · SMA20: $241.92 · SMA50: $232.43

6-Pillar Scorecard Institutional Category Breakdown (EW 2 – 4 RMD)

Columns: Metric · EW · RMD
1. Valuation Multiples RMD
Forward P/E 31.6x 19.8x
Trailing P/E 61.5x 21.8x
PEG Ratio 2.33x 1.28x
EV / Revenue 8.8x 5.8x
2. Growth & Scale EW
Revenue Growth (YoY) +10.5% +5.9%
Earnings Growth (YoY) +6.7% +23.2%
TTM Revenue (USD) $6.67B $5.73B
Market Cap $60.8B $33.6B
3. Profitability & Quality RMD
Gross Margin 78.0% 61.8%
Operating Margin 28.8% 34.0%
Net Profit Margin 15.3% 27.8%
Return on Equity (ROE) 9.3% 26.4%
4. Balance Sheet & Cash Flow RMD
Cash Generation (TTM) $1.42B $1.59B
Cash Flow Margin 21.3% 27.7%
Net Cash / Leverage $2.41B Net Cash $400M Net Cash
Dividend Yield None (0.00%) 1.03%
5. Options & Positioning RMD
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 24.6% (34th %ile) 28.2% (22nd %ile)
Put/Call OI Skew N/A 2.00x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup ACCUMULATION · Markup
6. R&D & Supply-Chain Moat EW
OpEx & R&D Intensity 49.2% of Rev ($3.28B) 27.8% of Rev ($1.59B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat High-Margin Pricing Power Moat
Supply-Chain Role Medical Devices Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EW (4) vs RMD (6)
Institutional Metric EW RMD Criterion Row Edge
Market Capitalization
Scale
$60.8B $33.6B Larger Scale EW
Trailing P/E Ratio
Valuation
61.5x 21.8x Lower Multiple RMD
Forward P/E Ratio
Valuation
31.6x 19.8x Lower Multiple RMD
Revenue Growth (YoY)
Growth
+10.5% +5.9% Higher Growth EW
Operating Margin (TTM)
Profitability
28.8% 34.0% Higher Margin RMD
Net Profit Margin
Profitability
15.3% 27.8% Higher Margin RMD
Return on Equity (ROE)
Capital Efficiency
9.3% 26.4% Higher ROE RMD
52-Week Range Position
Momentum
96% ($75–$108) 61% ($180–$278) Stronger Trend EW
Beta / 30D Volatility
Risk Regime
0.44β · 24% Vol 0.41β · 43% Vol Lower Realized Risk EW
Unified Institutional Score
Composite Signal
31.5 / 100 (SELL) 59.0 / 100 (HOLD) Higher Composite RMD
Trailing 12M Revenue (USD)
Operating Scale
$6.67B $5.73B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
78.0% 61.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.33x PEG · 8.8x EV/Rev 1.28x PEG · 5.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.42B ($2.41B Net Cash) $1.59B ($400M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EW +23.0 pp
EW: +23.16% · RMD: +0.16%
3M Horizon EW +8.43 pp
EW: +17.23% · RMD: +8.8%
6M Horizon EW +12.21 pp
EW: +29.45% · RMD: +17.24%
1Y Horizon EW +28.92 pp
EW: +23.86% · RMD: -5.06%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period EW Revenue RMD Revenue EW Op. Margin RMD Op. Margin Margin Leader
FY2019 $4.35B $2.61B 26.4% 22.2% EW
FY2020 $4.39B $2.96B 20.5% 27.4% RMD
FY2021 $5.23B $3.20B 32.3% 28.3% EW
FY2022 $4.46B $3.58B 33.6% 28.0% EW
FY2023 $5.01B $4.22B 26.1% 26.8% RMD
FY2024 $5.44B $4.69B 25.3% 28.2% RMD
FY2025 $6.07B $5.15B 20.8% 32.7% RMD
FY2026 N/A $5.65B N/A 33.4% RMD

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EW UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 24.6%
IV Percentile 34th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EW Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RMD CONSOLIDATION
58d in phase · OBV ACCUMULATION
Current IV 28.2%
IV Percentile 22nd %ile
Put/Call OI Skew 2.00x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact RMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EW Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $60.8B market capitalization and 28.8% operating margin.
OpEx & R&D Reinvestment 49.2% of Rev ($3.28B)
90D Engineering Disclosures 0 Published
RMD Moat Profile High-Margin Pricing Power Moat
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $33.6B market capitalization and 34.0% operating margin.
OpEx & R&D Reinvestment 27.8% of Rev ($1.59B)
90D Engineering Disclosures 0 Published

Investor FAQ EW vs RMD Key Questions & Quantitative Answers

As of Nov 16, 2026, ResMed Inc. (RMD) is the stronger overall head-to-head candidate over Edwards Lifesciences Corp (EW) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). EW carries a Unified Composite Score of 31.5/100 (SELL) at $106.66 (31.6x Forward P/E, 28.8% operating margin), whereas RMD carries 59.0/100 (HOLD) at $239.34 (19.8x Forward P/E, 34.0% operating margin). Technically, EW sits in a Markup phase (RSI 79.4, UNCLASSIFIED options structure) and RMD sits in a Markup phase (RSI 54.8, CONSOLIDATION options structure).

EW leads the Growth & Scale pillar: EW posts +10.5% YoY revenue growth and +6.7% YoY earnings growth on $6.67B TTM revenue (78.0% gross margin, 28.8% operating margin), compared with RMD at +5.9% YoY revenue growth and +23.2% YoY earnings growth on $5.73B TTM revenue (61.8% gross margin, 34.0% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), EW cumulative revenue shifted +39.5% while RMD shifted +116.5%. In operating R&D and SG&A reinvestment, EW deploys 49.2% of Rev ($3.28B) (0 90-day corporate R&D disclosures) versus 27.8% of Rev ($1.59B) (0 disclosures) for RMD.

RMD screens cheaper on headline valuation multiples. EW trades at 31.6x Forward P/E, 61.5x Trailing P/E, 2.33x PEG, and 8.8x EV/Revenue (21.3% FCF margin), whereas RMD trades at 19.8x Forward P/E, 21.8x Trailing P/E, 1.28x PEG, and 5.8x EV/Revenue (27.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EW (9.3% ROE) versus RMD (26.4% ROE) capital efficiency.

In options market volatility and institutional positioning, EW carries 24.6% implied volatility (34th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.44β · 24% Vol realized risk). By comparison, RMD carries 28.2% implied volatility (22nd %ile, Compressed (<25th %ile)), a 2.00x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.41β · 43% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.